{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:05:06Z","timestamp":1793855106875,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41591-025-03951-w","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:04:00Z","timestamp":1758791040000},"page":"3553-3559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-0067","authenticated-orcid":false,"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Vavere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-6785","authenticated-orcid":false,"given":"Dimitris","family":"Kardassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe A.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-8151","authenticated-orcid":false,"suffix":"Jr.","given":"Antonio A. De Paiva","family":"Fagundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ardissino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-7743","authenticated-orcid":false,"given":"Eri","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton Oude","family":"Ophuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Selvanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lopez-Sendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Wojakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-8892","authenticated-orcid":false,"given":"Azfar","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8756-6995","authenticated-orcid":false,"given":"Joao A. C.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-9610","authenticated-orcid":false,"given":"Michael T.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-4827","authenticated-orcid":false,"given":"Borek","family":"Foldyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-1747","authenticated-orcid":false,"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Turton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Coll\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gabrielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the GOLDILOX-TIMI 69 Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"3951_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/714653","volume":"2013","author":"G Maiolino","year":"2013","unstructured":"Maiolino, G. et al. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013, 714653 (2013).","journal-title":"Mediators Inflamm."},{"key":"3951_CR2","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1161\/01.CIR.99.24.3110","volume":"99","author":"H Kataoka","year":"1999","unstructured":"Kataoka, H. et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99, 3110\u20133117 (1999).","journal-title":"Circulation"},{"key":"3951_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/386073a0","volume":"386","author":"T Sawamura","year":"1997","unstructured":"Sawamura, T. et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73\u201377 (1997).","journal-title":"Nature"},{"key":"3951_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S0006-291X(02)02905-4","volume":"300","author":"K Kataoka","year":"2003","unstructured":"Kataoka, K. et al. LOX-1 pathway affects the extent of myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 300, 656\u2013660 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3951_CR5","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.jacc.2017.04.010","volume":"69","author":"NVK Pothineni","year":"2017","unstructured":"Pothineni, N. V. K. et al. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J. Am. Coll. Cardiol. 69, 2759\u20132768 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3951_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1161\/01.ATV.21.6.955","volume":"21","author":"H Kataoka","year":"2001","unstructured":"Kataoka, H. et al. Oxidized LDL modulates Bax\/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arter. Thromb. Vasc. Biol. 21, 955\u2013960 (2001).","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"3951_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/eurheartj\/ehaa770","volume":"42","author":"A Akhmedov","year":"2021","unstructured":"Akhmedov, A. et al. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur. Heart J. 42, 1797\u20131807 (2021).","journal-title":"Eur. Heart J."},{"key":"3951_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbrc.2020.01.156","volume":"524","author":"M Villa","year":"2020","unstructured":"Villa, M. et al. Pro-fibrotic effect of oxidized LDL in cardiac myofibroblasts. Biochem. Biophys. Res. Commun. 524, 696\u2013701 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3951_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/gt.2011.133","volume":"19","author":"J Lu","year":"2012","unstructured":"Lu, J. et al. LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse. Gene Ther. 19, 522\u2013531 (2012).","journal-title":"Gene Ther."},{"key":"3951_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.108.115287","volume":"52","author":"C Hu","year":"2008","unstructured":"Hu, C. et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension 52, 556\u2013562 (2008).","journal-title":"Hypertension"},{"key":"3951_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCRESAHA.107.149724","volume":"100","author":"JL Mehta","year":"2007","unstructured":"Mehta, J. L. et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 100, 1634\u20131642 (2007).","journal-title":"Circ. Res."},{"key":"3951_CR12","doi-asserted-by":"publisher","first-page":"e0154994","DOI":"10.1371\/journal.pone.0154994","volume":"11","author":"C Yokoyama","year":"2016","unstructured":"Yokoyama, C. et al. Deletion of LOX-1 protects against heart failure induced by doxorubicin. PLoS ONE 11, e0154994 (2016).","journal-title":"PLoS ONE"},{"key":"3951_CR13","doi-asserted-by":"publisher","first-page":"e027540","DOI":"10.1161\/JAHA.122.027540","volume":"12","author":"AL Vavere","year":"2023","unstructured":"Vavere, A. L. et al. Lectin-like oxidized low-density lipoprotein receptor 1 inhibition in type 2 diabetes: phase 1 results. J. Am. Heart Assoc. 12, e027540 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"3951_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/01.RES.0000174286.73200.d4","volume":"97","author":"K Inoue","year":"2005","unstructured":"Inoue, K., Arai, Y., Kurihara, H., Kita, T. & Sawamura, T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ. Res. 97, 176\u2013184 (2005).","journal-title":"Circ. Res."},{"key":"3951_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1161\/01.RES.0000174563.62625.8e","volume":"97","author":"R Mango","year":"2005","unstructured":"Mango, R. et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ. Res. 97, 152\u2013158 (2005).","journal-title":"Circ. Res."},{"key":"3951_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/jmg.40.12.933","volume":"40","author":"R Mango","year":"2003","unstructured":"Mango, R. et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J. Med Genet 40, 933\u2013936 (2003).","journal-title":"J. Med Genet"},{"key":"3951_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0006-291X(03)00326-7","volume":"303","author":"M Tatsuguchi","year":"2003","unstructured":"Tatsuguchi, M. et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem. Biophys. Res. Commun. 303, 247\u2013250 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3951_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s42004-020-0321-2","volume":"3","author":"G Schnapp","year":"2020","unstructured":"Schnapp, G. et al. A small-molecule inhibitor of lectin-like oxidized LDL receptor-1 acts by stabilizing an inactive receptor tetramer state. Commun. Chem. 3, 75 (2020).","journal-title":"Commun. Chem."},{"key":"3951_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/01.ATV.20.3.715","volume":"20","author":"T Murase","year":"2000","unstructured":"Murase, T. et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arter. Thromb. Vasc. Biol. 20, 715\u2013720 (2000).","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"3951_CR20","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.ijcard.2013.04.110","volume":"168","author":"N Kobayashi","year":"2013","unstructured":"Kobayashi, N. et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma: verification by optical coherence tomography. Int. J. Cardiol. 168, 3217\u20133223 (2013).","journal-title":"Int. J. Cardiol."},{"key":"3951_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jacbts.2017.07.007","volume":"2","author":"NEJ West","year":"2017","unstructured":"West, N. E. J. et al. Percutaneous sampling of local biomolecule gradients across coronary artery atherosclerotic plaques. JACC Basic Transl. Sci. 2, 646\u2013654 (2017).","journal-title":"JACC Basic Transl. Sci."},{"key":"3951_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/eurheartj\/ehac143","volume":"43","author":"S Kraler","year":"2022","unstructured":"Kraler, S. et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur. Heart J. 43, 1849\u20131860 (2022).","journal-title":"Eur. Heart J."},{"key":"3951_CR23","doi-asserted-by":"publisher","first-page":"e013803","DOI":"10.1161\/JAHA.119.013803","volume":"9","author":"A Hofmann","year":"2020","unstructured":"Hofmann, A., Brunssen, C., Wolk, S., Reeps, C. & Morawietz, H. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection? J. Am. Heart Assoc. 9, e013803 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"3951_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamadermatol.2019.3595","volume":"156","author":"AK Dey","year":"2020","unstructured":"Dey, A. K. et al. Association between soluble lectinlike oxidized low-density lipoprotein receptor-1 and coronary artery disease in psoriasis. JAMA Dermatol. 156, 151\u2013157 (2020).","journal-title":"JAMA Dermatol."},{"key":"3951_CR25","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","volume":"2","author":"J Lo","year":"2015","unstructured":"Lo, J. et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2, e52\u2013e63 (2015).","journal-title":"Lancet HIV"},{"key":"3951_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.122.059325","volume":"146","author":"MP Bonaca","year":"2022","unstructured":"Bonaca, M. P. et al. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation 146, 907\u2013916 (2022).","journal-title":"Circulation"},{"key":"3951_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","volume":"9","author":"MT Lu","year":"2024","unstructured":"Lu, M. T. et al. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial. JAMA Cardiol. 9, 323\u2013334 (2024).","journal-title":"JAMA Cardiol."},{"key":"3951_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jcct.2024.05.232","volume":"18","author":"K Nieman","year":"2024","unstructured":"Nieman, K. et al. Standards for quantitative assessments by coronary computed tomography angiography (CCTA): an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). J. Cardiovasc. Comput. Tomogr. 18, 429\u2013443 (2024).","journal-title":"J. Cardiovasc. Comput. Tomogr."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03951-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03951-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03951-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:48:21Z","timestamp":1760680101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03951-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3951"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03951-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.O.D. has received grant funding via Brigham and Women\u2019s Hospital from Novartis, Amgen, AstraZeneca and Janssen, and has received consulting and\/or IDMC fees from Novartis, Amgen, AstraZeneca, Verve, Novo Nordisk, New Amsterdam and Janssen. D.A.M. reports consulting fees from Abbott Laboratories, ARCA Biopharma, InCarda, Inflammatix, Merck & Co, Novartis, Regeneron and Roche Diagnostics. M.E.F. has research grants from Novo Nordisk and Novartis and serves on the data safety monitoring board for AstraZeneca. F.A.M. reports consulting fees from Janssen. D.K., A.C., A.L.V. and M.T. are employees of AstraZeneca and have stock options in AstraZeneca. R.G. is a former employee of MedImmune\/Astrazeneca and a current employee of Regeneron Pharmaceuticals with stock ownership in AstraZeneca and Regeneron Pharmaceuticals. J.S. reports research grant support from Biotronik, Sanofi, Pfizer and Attralus; received consulting fees from BMS, Sanofi and Attralus; and received speaker bureau fees from Pfizer, AstraZeneca, Boehringer Ingelheim, Novartis, Bayer, Sanofi, Biotronik, CircleCVi, Takeda, Amicus and BMS. E.K. reports receiving lecture fees from Astellas, Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly Japan KK, Daiichi-Sankyo, Menarini, Ono Pharmaceutical, Ootsuka Pharmaceutical, MSD KK, Takeda Pharmaceutical, Tanabe-Mitsubishi, Bayer and Pfizer; and reports consultant fees or research fund from Boehringer Ingelheim, Bayer, Novo Nordisk, Daiichi-Sankyo, Abbott, Ono Pharmaceutical and Tanabe-Mitsubishi. A.Z. has received grant support from Novartis and consulting and\/or lecture fees from AstraZeneca, Novartis, Boehringer Ingelheim, Amarin, Pfizer, Sanofi, Amgen, Eli Lilly and Novo Nordisk. A.G. is a former full-time employee of AstraZeneca at the time of study execution, and current full-time employee and stockholder of Ribocure Pharmaceuticals. M.L.O.D., D.A.M., M.S.S., J.K., J.-G.P. and S.A.M. are members of the TIMI Study Group and have received research grant support through Brigham and Women\u2019s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis, Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics and Verve Therapeutics and have received consulting fees Amgen, AMPEL BioSolutions, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr. Reddy\u2019s Laboratories, Fibrogen, Merck, Moderna, Novo Nordisk, Precision BioSciences and Silence Therapeutics. B.F. reports grant support from AstraZeneca\/Medimmune, MedTrace, Ionis and NIH\/NHLBI. J.L.-S. reports research grant from AstraZeneca, Bayer\/Johnson & Johnson, Pfizer and Amgen, and has received speaker honoraria from Menarini. A.A.D.P.F. reports consulting fees from AstraZeneca, Novartis, Boehringer Ingelheim, Merck Sharp Dohme and Mundipharma. M.T.L. has received research funding through the Massachusetts General Hospital from AstraZeneca, American Heart Association, Ionis, Johnson & Johnson Innovation, MedImmune, National Academy of Medicine, National Heart, Lung, and Blood Institute and Risk Management Foundation of the Harvard Medical Institutions. J.A.C.L. reports grant funding from AstraZeneca and Canon Medical Systems. M.S.S. reports research grant support through Brigham and Women\u2019s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis, Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics and Verve Therapeutics, and has received consulting fees from Amgen, AMPEL BioSolutions, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr. Reddy\u2019s Laboratories, Fibrogen, Merck, Moderna, Novo Nordisk, Precision BioSciences and Silence Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}